当前位置:
X-MOL 学术
›
Diabetes Obes. Metab.
›
论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Efficacy and safety of sotagliflozin in patients with type 2 diabetes and severe renal impairment
Diabetes, Obesity and Metabolism ( IF 5.8 ) Pub Date : 2021-08-02 , DOI: 10.1111/dom.14513 David Z. I. Cherney 1 , Ele Ferrannini 2 , Guillermo E. Umpierrez 3 , Anne L. Peters 4 , Julio Rosenstock 5 , Amy K. Carroll 6 , Pablo Lapuerta 6 , Phillip Banks 6 , Rajiv Agarwal 7
Diabetes, Obesity and Metabolism ( IF 5.8 ) Pub Date : 2021-08-02 , DOI: 10.1111/dom.14513 David Z. I. Cherney 1 , Ele Ferrannini 2 , Guillermo E. Umpierrez 3 , Anne L. Peters 4 , Julio Rosenstock 5 , Amy K. Carroll 6 , Pablo Lapuerta 6 , Phillip Banks 6 , Rajiv Agarwal 7
Affiliation
To assess the efficacy and safety of sotagliflozin, a dual inhibitor of sodium-glucose cotransporter-1 and -2, in adults with type 2 diabetes (T2D) and stage 4 chronic kidney disease (CKD4).
中文翻译:
sotagliflozin在2型糖尿病合并重度肾功能损害患者中的疗效和安全性
评估 sotagliflozin(一种钠-葡萄糖协同转运蛋白-1 和-2 的双重抑制剂)在成人 2 型糖尿病 (T2D) 和 4 期慢性肾病 (CKD4) 中的疗效和安全性。
更新日期:2021-08-02
中文翻译:
sotagliflozin在2型糖尿病合并重度肾功能损害患者中的疗效和安全性
评估 sotagliflozin(一种钠-葡萄糖协同转运蛋白-1 和-2 的双重抑制剂)在成人 2 型糖尿病 (T2D) 和 4 期慢性肾病 (CKD4) 中的疗效和安全性。